Poniard Pharmaceuticals(OTC) PARD

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative cancer treatments. The company’s flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, including small cell lung, colorectal, prostate, and ovarian cancers.

Products and Services

• Picoplatin: A platinum-based therapy for multiple cancer types
• Clinical trials: Advanced through pivotal Phase III and Phase II studies
• Research: Ongoing exploration of oral formulations for solid tumors

Growth Outlook

• Picoplatin has shown promise in pivotal Phase III trials for small cell lung cancer
• Ongoing studies may expand treatment options for colorectal and prostate cancers
• Potential market entry could significantly enhance revenue opportunities

Financial Highlights

• Recent quarterly net income reported at -$3.77 million
• Cash and cash equivalents totaled $1.98 million as of September 30, 2011
• Current ratio stands at 3.23, indicating strong short-term financial health

Poniard Pharmaceuticals, Inc. operates in the biotechnology sector, with a focus on addressing unmet medical needs in cancer treatment. The company has made significant strides in clinical development, particularly with Picoplatin, which has advanced through various stages of trials. The potential for market introduction of this therapy could position Poniard favorably within the competitive landscape of oncology treatments. Financially, the company has faced challenges, as indicated by recent net income figures. However, the current ratio suggests a solid liquidity position, allowing for continued investment in research and development. The cash reserves, while limited, provide a foundation for ongoing operations and potential future growth. Investors may find Poniard Pharmaceuticals, Inc. an intriguing opportunity, particularly given the advancements in its clinical pipeline and the potential for future revenue generation through successful product launches. The company's commitment to developing innovative cancer therapies aligns with the growing demand for effective cancer treatments in the healthcare market.